elon musk glp 1 is on the weight loss drug bandwagon Elon Musk publicly shared that

The emergence of CVD is dependent on a compromised mucosal barrier and decreased intestinal mucosal barrier function, and is mostly caused by gram-negative microbes, such as lipopolysaccharide (LPS), which plays a significant role in the emergence of cardiometabolic diseases (37, 38)

Ongoing clinical trials in peripheral vascular disease, neuropsychiatric and substance use disorders, metabolic liver disease, arthritis, hypertension and neurodegenerative disorders may broaden indications for GLP-1-based therapeutics

[13] Older adults are particularly susceptible

Metabolic benefits beyond weight loss Weight loss is the headline, but both medications produce metabolic improvements that extend far beyond the number on the scale